Edward Tenthoff

Moderna, Inc. (NASDAQ: MRNA) shares have followed a downtrend ever since completing a double top formation in late September. After bottoming in early October, the stock reversed course and moved higher in anticipation of authorization for its COVID-19 booster shot. U.S. Food and Drug...

Moderna Inc (NASDAQ: MRNA) has initiated a Phase 1/2 study and dosed the first patient with mRNA1010, its quadrivalent vaccine for seasonal flu. The candidate is designed to target lineup lineages that include influenza A H1N1, H3N2, and influenza B Yamagata and Victoria. The 180-subject...

Moderna Inc (NASDAQ: MRNA) shares were trading at new highs Monday following the release of positive interim Phase 1 immunogenicity and safety data for its mRNA-1273 coronavirus vaccine candidate.  The Moderna Analysts Goldman Sachs analyst Salveen Richter maintained a Buy rating on Moderna...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) stock tanked 15 percent Thursday after the company announced a new $3.7-billion deal to license its ARO-HBV treatment for chronic hepatitis B to Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals. Investors clearly weren’t...

The Food and Drug Administration approved Array Biopharma Inc (NASDAQ: ARRY)’s combination therapy of Mektovi and Braftovi in the treatment of BRAF-mutant melanoma on Wednesday.  The stock, which rallied ahead of the news, subsequently plunged as investors walked with profits — but...

Piper Jaffray reiterated its Overweight rating and $106 target price on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) despite discontinuation of ENDEAVOUR trial of Revusiran as it sees value in the company’s RNAi pipeline. “While we await clinical data, we believe the death imbalance...

It’s hard to find a silver lining following news that sends a stock crashing 84.5 percent in one day. However, following devastating news that the Phase III RESOLVE trial of its RSV vaccine failed to deliver the desired results, Novavax, Inc. (NASDAQ: NVAX) shareholders are looking for any...

Shares of Arrowhead Research Corp (NASDAQ: ARWR) lost more than 50 percent from a year ago. Edward Tenthoff of Piper Jaffray left Arrowhead's R&D day "more confident" that the company's ARC-520 is an active drug for HBV. Tenthoff maintained an Overweight rating with a price target boosted to $...

Biotech analysts at Piper Jaffray stated in a note on Wednesday that "we are buyers on weakness" of select biotech names that boast strong enough balance sheets to "make it through" upcoming value-driving events. The analysts, led by Edward Tenthoff, singled out Vertex Pharmaceuticals Incorporated...